Clover Health Investments (CLOV) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

2024 achievements and strategic focus

• Achieved material Adjusted EBITDA profitability for 2024 without raising capital, meeting a key goal.

• Delivered approximately 27% year-over-year Medicare Advantage membership growth, reaching about 100,000 members, with 95% enrolled in 4-Star plans.

• Secured double upgrades in Star Ratings, reaching 3.5 stars for 2025 and 4 stars for 2026 payment year for flagship PPO plans.

• Maintained strong loss ratios and reinvested margins into member benefits, sustaining plan competitiveness.

• Expanded home care footprint in Georgia and maintained strong retention in core New Jersey markets.

Technology platform and care model

• Developed Clover Assistant, a technology platform synthesizing 100+ data sources and leveraging AI and proprietary models to provide actionable insights to physicians.

• Demonstrated improved clinical outcomes, including earlier detection and management of chronic diseases like CKD and diabetes.

• Medication adherence improved by about 5% on the day of a Clover Assistant visit and remained about 3% higher 90 days post-visit.

• Home-based care model for high-acuity members led to significant MCR improvement from 2021 to 2024.

• Platform empowers physicians to deliver value-based care while reducing total cost of care.

Quality and market leadership

• Achieved a 4.94/5 HEDIS score for 2025, the highest among large PPO plans nationwide.

• Outperformed national medians on key readmission prevention and care transition measures by 300–2,800 basis points.

• Majority of new members switched from other Medicare Advantage plans, with strong retention and a profitable returning cohort.

• Positioned for further MA market expansion, especially in New Jersey, as PPO plans outpace HMO growth nationally.

• Industry-leading loss ratios: MCR at 75.6% and BER at 80.6% as of Q3 2024.